





Blood 142 (2023) 3082-3084

The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

624.HODGKIN LYMPHOMAS AND T/NK CELL LYMPHOMAS: CLINICAL AND EPIDEMIOLOGICAL

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

David Lavie¹, John Timmerman, MD², Ramón García-Sanz, MD PhD³, Won Seog Kim, MD MPH, PhD⁴, Tae Min Kim, MD PhD⁵, Abraham Avigdor, MD⁶, Daan Dierickx⁷, Deepa Jagadeesh, MD⁸, Daniel L. Molin, MD⁹, Muhit Ozcan, MD¹⁰, Omur Gokmen Sevindik, MD¹¹, Hayder Saeed, MD¹², Yulia Sidi¹³, Pallavi Pillai, MD¹³, Patricia Marinello, PharmD¹³, Alex F. Herrera, MD¹⁴

- ¹Hadassah Medical Center, Jerusalem, Israel
- ²UCLA Medical Center, Los Angeles, CA
- ³University Hospital of Salamanca, Salamanca, Spain
- ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
- ⁵Seoul National University Hospital, Seoul, Korea, Republic of (South)
- ⁶Sheba Medical Center-Tel HaShomer, Ramat Gan, Israel
- ⁷University Hospitals Leuven, Leuven, Belgium
- ⁸Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
- ⁹Uppsala University, Uppsala, Sweden
- ¹⁰Hematology Department, Ankara University School of Medicine, Ankara, Turkey
- ¹¹ Istanbul Medipol University, International School of Medicine, Istanbul, Turkey
- ¹²Moffitt Cancer Center, Tampa, FL
- ¹³Merck & Co., Inc., Rahway, NJ
- ¹⁴City of Hope, Duarte, CA

Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. However, most patients eventually develop progressive disease and optimal therapy after anti-PD-1 failure has not been determined. The inhibitory checkpoint receptor, lymphocyte-activation gene 3 (LAG-3) is expressed in cHL tumor microenvironments and upregulation of LAG-3 is considered to play an important role in anti-PD-1 resistance. Favezelimab (MK-4280) is a humanized immunoglobulin G4 antibody that binds to LAG-3 and blocks interaction with major histocompatibility complex Class II ligands. Results from the ongoing phase 1/2 MK-4280-003 study of the combination of favezelimab and pembrolizumab demonstrated manageable safety and promising antitumor activity in patients with anti-PD-1-refractory R/R cHL. The randomized, open-label, parallel group, active-controlled, phase 3 KEYFORM-008 study (NCT05508867) is designed to evaluate efficacy and safety of the coformulation of favezelimab and pembrolizumab and pembrolizumab versus physician's choice of chemotherapy in patients with anti-PD-1-refractory R/R cHL.

Study Design and Methods: Patients \geq 18 years old, with histologically confirmed R/R cHL, an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2, and adequate organ function are eligible. Patients must have exhausted all available treatment options with known clinical benefit, including having progressed on anti-PD-1-based therapy and being ineligible for or having failed autologous stem cell transplant (ASCT). In addition, patients should also have been ineligible for brentuximab vedotin (BV), relapsed or failed to respond to BV or discontinued BV due to toxicity. Patients with a history of central nervous system (CNS) metastases or active CNS involvement are excluded. Approximately 360 patients will be enrolled and randomly assigned 1:1 to receive coformulated favezelimab 800 mg and pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) or physician's choice of chemotherapy (gemcitabine 800-1200 mg/m² IV on days 1 and 8 of a 21-day cycle or bendamustine 90-120 mg/m² IV on days 1 and 2 of either a 21- or 28-day cycle). Randomization will be stratified by prior ASCT (yes vs no) and ECOG PS (0 or 1 vs 2). Treatment will continue for \leq 35 cycles for the favezelimab/pembrolizumab coformulation or \leq 6 cycles for chemotherapy or until disease progression, unacceptable toxicity, or withdrawal. Patients receiving physician's choice of chemotherapy with progressive disease confirmed by blinded independent central review (BICR)

POSTER ABSTRACTS

per Lugano criteria may be eligible to cross over to the favezelimab/pembrolizumab coformulation. Response assessments by positron emission tomography (PET) and computed tomography (CT) or magnetic resonance imaging (MRI) will be performed every 12 weeks (Q12W) until disease progression or trial discontinuation. Adverse events will be monitored throughout the study and graded per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The primary end point is progression-free survival (PFS) per Lugano criteria by BICR. Overall survival (OS) is a key secondary end point. Other secondary end points are objective response rate (ORR), duration of response (DOR) per Lugano criteria by BICR, and safety. Exploratory end points include PFS on subsequent anticancer therapy and health-related quality of life. PFS, OS, and DOR rates in each treatment group will be estimated using the Kaplan-Meier method. The Clopper-Pearson method will be used to estimate ORR with 95% CI. Patient-reported outcomes will be assessed using EORTC Quality Of Life Questionnaire C30 and the EuroQuol 5-dimension, 5-level questionnaire. Enrollment for this study is open in sites in Australia, Belgium, Brazil, Canada, China, Czech Republic, France, Germany, Israel, Poland, Spain, South Korea, Sweden, Switzerland, Turkey, UK, and USA.

©2023 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2023 ASCO Annual Meeting. All rights reserved.

Disclosures Lavie: MSD: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel/Accommodation expenses, lecture; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory Board and Travel/Accommodation expenses; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Lecture; Medisson: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Other: Advisory Board; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Lecture. Timmerman: DAVA Oncology: Consultancy; Kite/Gilead: Consultancy, Honoraria, Research Funding; BMS: Other: Travel/Accommodations/Expenses, Research Funding; Oncovalent Therapeutics: Consultancy; Merck & Co., Inc.: Research Funding. García-Sanz: Abbvie: Consultancy; Ideogen: Consultancy; Miltenyi: Consultancy; ADC Therapeutics America: Consultancy; Lilly: Consultancy; Incyte: Consultancy, Honoraria; Kyowa Kirin: Consultancy; Novartis: Consultancy, Honoraria; Eusa Pharma: Honoraria; Takeda: Consultancy, Honoraria, Other: TRAVEL, AC-COMODATIONS, EXPENSES, Research Funding, Speakers Bureau; Gilead/Kite: Consultancy, Honoraria, Other: TRAVEL, AC-COMMODATIONS, EXPENSES, Research Funding; Janssen: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODA-TIONS, EXPENSES; Roche: Consultancy, Honoraria; BeiGene: Consultancy, Honoraria, Other: TRAVEL, ACCOMODATIONS, EXPENSES, Speakers Bureau; invivo scribe (IVS): Patents & Royalties. Kim: Boryung: Research Funding; Kyowa-Kirin: Research Funding; Beigene: Research Funding; Donga: Research Funding; Sanofi: Research Funding; Roche: Research Funding. Kim: Yuhan: Consultancy; Samsung Bioepis: Consultancy; MedImmune: Consultancy, Honoraria, Other: Uncompensated relationship; F. Hoffmann-La Roche Ltd: Consultancy; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Uncompensated relationship; Regeneron: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Uncompensated relationship; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; IMBDx, Inc.: Honoraria, Speakers Bureau; Boryung: Consultancy, Other: Uncompensated relationship; BeiGene: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Honoraria, Other: Uncompensated relationship, Research Funding; Amgen: Honoraria. Avigdor: AbbVie: Membership on an entity's Board of Directors or advisory committees, Other: Travel/Accommodations/Expenses; BMS: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; MSD: Research Funding. Dierickx: Sanofi Genzyme: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Atara Biotherapeutics: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Pierre Fabre: Honoraria; Roche: Consultancy; Novartis: Consultancy; Amgen: Consultancy. Jagadeesh: Affimed: Membership on an entity's Board of Directors or advisory committees; Trillium Pharmaceuticals: Research Funding; Seagen: Research Funding; MEI Pharma: Research Funding; Regeneron Pharmaceuticals: Research Funding; ATARA Biotherapeutics: Research Funding; Debio Pharma: Research Funding; LOXO Pharmaceuticals: Research Funding; AstraZeneca: Research Funding; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees. Molin: Takeda: Honoraria; Roche: Honoraria; MSD: Honoraria; BMS: Honoraria. Ozcan: Acerta: Research Funding; Janssen: Research Funding; Bayer: Research Funding; Abbvie: Other: Travel/Accommodations/Expenses, Research Funding; MSD: Research Funding; Roche: Research Funding; Takeda: Research Funding; Pfizer: Research Funding; PSI: Research Funding; Sandoz: Other: Travel/Accommodations/Expenses. Gokmen Sevindik: Jannsen: Honoraria; Amgen: Honoraria; BMS: Honoraria; MSD: Honoraria; Takeda: Honoraria. Saeed: Epizyme: Consultancy; Morphosis: Honoraria; Novarits: Consultancy. Sidi: Merck & Co., Inc.: Current Employment, Current equity holder in publicly-traded company. Pillai: Merck & Co., Inc.: Current Employment, Current equity holder in publicly-traded company. Marinello: Merck & Co., Inc.: Current Employment, Current equity holder in publicly-traded company. Herrera: Adicet Bio: Consultancy; Merck: Consultancy, Research Funding; Kite, a Gilead Company: Research Funding; AstraZeneca/MedImmune: Consultancy; Genentech/Roche: Consultancy, Research Funding; Pfizer: Consultancy; Genmab: Consultancy; Seattle Genetics: Consultancy, Research Funding; Regeneron: Consultancy; BMS: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding; ADC Therapeutics: Consultancy, Research Funding; Takeda: Consultancy; Karyopharm Therapeutics: Consultancy; Tubulis GmbH: Consultancy; Caribou Biosciences: Consultancy; Allogene Therapeutics: Consultancy; AbbVie: Consultancy; Gilead Sciences: Research Funding; AstraZeneca: Research Funding.

https://doi.org/10.1182/blood-2023-182119